发明申请
US20050096367A1 Pharmaceutical composition for suppression of the expression of ATP citrate lyase and use thereof
审中-公开
用于抑制ATP柠檬酸裂合酶表达的药物组合物及其用途
- 专利标题： Pharmaceutical composition for suppression of the expression of ATP citrate lyase and use thereof
- 专利标题（中）： 用于抑制ATP柠檬酸裂合酶表达的药物组合物及其用途
-
申请号： US10997873申请日： 2004-11-29
-
公开(公告)号： US20050096367A1公开(公告)日： 2005-05-05
- 发明人: Yoshiro Kitahara , Tomohisa Okutsu , Akira Mitsui , Akira Okano
- 申请人： Yoshiro Kitahara , Tomohisa Okutsu , Akira Mitsui , Akira Okano
- 优先权： JP2002-154397 20020528
- 主分类号： A61K31/00
- IPC分类号： A61K31/00 ; A61K31/175 ; A61K31/198 ; A61K31/426
摘要：
The present invention provides a pharmaceutical composition for suppression of the expression of ATP citrate lyase, which contains a compound that suppresses the expression of ATP citrate lyase by the in vivo administration. The compounds suppress the expression of ATP citrate lyase by the in vivo administration include insulin secretagogues such as nateglinide. This pharmaceutical composition is effective in preventing, improving and treating metabolic syndrome, in particular, liver disorders related to abnormal lipid metabolism such as fatty liver and NASH.